Latest News and Press Releases

PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn’s disease (FSCD) and ulcerative colitis (UC), to address significant unmet medical...

KIGALI, Rwanda and SAN FRANCISCO and AUBAGNE, France, July 29, 2025 (GLOBE NEWSWIRE) -- Bio Usawa Biotechnology, Ltd. (Bio Usawa), a leading African biotechnology firm, and Sartorius Stedim Biotech,...

Carlsbad, CA, July 23, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing...

Austin, TX, USA, July 16, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Ultomiris Drug Market Size, Trends and Insights By Indication (Paroxysmal...

Claimable Honored in Fast Company’s 2025 World Changing Ideas Awards. Recognition comes as Claimable expands its impact with support for GLP-1 appeals.

Medicovestor and Sanyou team up to develop first-in-class chemoimmunotherapy ADCs, combining AI antibody tech with novel dual-targeting platforms.

Oxford Healthspan announces the continued U.S. expansion of its food-derived spermidine supplements – Primeadine®.

Conduit Pharmaceuticals Provides Update on Nasdaq Stock Market Hearing Panel

Photys Therapeutics exclusively in-licensed Phase 1-ready IRAK4 degrader from Polymed; plan to start Phase 1 later this year for autoimmune indications

Conduit Pharmaceuticals Announces Debt Repayment and Partial Conversion of Senior Secured Note